An Attenuated HSV-1-Derived Malaria Vaccine Expressing Liver-Stage Exported Proteins Induces Sterilizing Protection against Infectious Sporozoite Challenge

Creative Commons License

Rider P. J. F., KAMIL M., Yilmaz I., Atmaca H. N., Kalkan-Yazici M., Ziya Doymaz M., ...More

VACCINES, vol.10, no.2, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 10 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.3390/vaccines10020300
  • Journal Name: VACCINES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, BIOSIS, EMBASE, Directory of Open Access Journals
  • Keywords: malaria vaccine, VC2, liver stage, EXP1, UIS3, TMP21, intramuscular, subcutaneous, HSV-1, viral vector
  • Bezmialem Vakıf University Affiliated: Yes

Abstract

Here, we present the construction of an attenuated herpes simplex virus type-1 (HSV-1)-vectored vaccine, expressing three liver-stage (LS) malaria parasite exported proteins (EXP1, UIS3 and TMP21) as fusion proteins with the VP26 viral capsid protein. Intramuscular and subcutaneous immunizations of mice with a pooled vaccine, composed of the three attenuated virus strains expressing each LS antigen, induced sterile protection against the intravenous challenge of Plasmodium yoelii 17X-NL salivary gland sporozoites. Our data suggest that this malaria vaccine may be effective in preventing malaria parasite infection using practical routes of immunization in humans.